Format

Send to

Choose Destination
Oncotarget. 2017 Jul 4;8(27):43915-43924. doi: 10.18632/oncotarget.14918.

A meta-analysis of HLA peptidome composition in different hematological entities: entity-specific dividing lines and "pan-leukemia" antigens.

Author information

1
Institute for Cell Biology, Department of Immunology, University of Tübingen, Tübingen, Germany.
2
Applied Bioinformatics, Center for Bioinformatics and Department of Computer Science, University of Tübingen, Tübingen, Germany.
3
Immatics Biotechnologies GmbH, Tübingen, Germany.
4
Department of Hematology and Oncology, University of Tübingen, Tübingen, Germany.
5
Department of Neurosurgery, University Hospital Zurich, University of Zurich, Zurich, Switzerland.
6
Department of Hematology, Oncology, Hemostaseology and SCT, University Hospital RWTH Aachen, Aachen, Germany.
7
University Hospital Leipzig, Department of Hematology and Oncology, Leipzig, Germany.
8
Clinical Cooperation Unit Translational Immunology, German Cancer Consortium (DKTK), DKFZ Partner Site Tübingen, Tübingen, Germany.
9
Quantitative Biology Center, University of Tübingen, Tübingen, Germany.
10
Biomolecular Interactions, Max Planck Institute for Developmental Biology, Tübingen, Germany.
11
German Cancer Consortium (DKTK), DKFZ Partner Site Tübingen, Tübingen, Germany.

Abstract

Hematological malignancies (HM) are highly amenable targets for immunotherapeutic intervention and may be effectively treated by antigen-specific T-cell based treatment. Recent studies demonstrate that physiologically occurring anti-cancer T-cell responses in certain HM entities target broadly presented non-mutated epitopes. HLA ligands are thus implied as prime targets for broadly applicable and antigen-specific off-the-shelf compounds. With the aim of assessing the presence of common targets shared among different HM which may enable addressing a larger patient collective we conducted a meta-analysis of 83 mass spectrometry-based HLA peptidome datasets (comprising 40,361 unique peptide identifications) across four major HM (19 AML, 16 CML, 35 CLL, and 13 MM/MCL samples) and investigated similarities and differences within the HLA presented antigenic landscape. We found the cancer HLA peptidome datasets to cluster specifically along entity and lineage lines, suggesting that the immunopeptidome directly reflects the differences in the underlying (tumor-)biology. In line with these findings, we only detected a small set of entity-spanning antigens, which were predominantly characterized by low presentation frequencies within the different patient cohorts. These findings suggest that design of T-cell immunotherapies for the treatment of HM should ideally be conducted in an entity-specific fashion.

KEYWORDS:

HLA; cancer immunotherapy; hematological malignancies; mass spectrometry; tumor antigen

PMID:
28159928
PMCID:
PMC5546449
DOI:
10.18632/oncotarget.14918
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Impact Journals, LLC Icon for PubMed Central
Loading ...
Support Center